Conversely, this was notable in individuals with anti-CCP2+/RF+ [i.e. 21/59 (35.6%) developed US subclinical synovitis within 2 years of follow-up] compared with individuals with positive anti-CCP2+ and negative RF [i.e. 28/161 (17.4%), P = 0.01] (Fig. 2d). Here, AGBL2 is linked to synovitis.